Gapping up
In reaction to earnings/guidance:
- IBKR +3.7%, UAL +3.2%, PSO +1.3% (Trading update), UCBI +0.9%, AUY +0.7% (Q4 and FY22 production results)
Other news:
- PRTK +8.2% (announces inclusion of NUZYRA (omadacycline) in China's National Reimbursement Drug List)
- MRNA +7.6% (RSV vaccine meets efficacy endpoints)
- BMO +3% (receives regulatory approval to acquire Bank of the West)
- GH +2.9% (to showcase new data)
- MITK +2.5% (retains its interim CFO)
- BGNE +2.2% (presents new research)
- LOB +2% (files mixed shelf)
- CSTL +1.8% (presents at 2023 Winter Clinical Dermatology Conference)
- PR +1.6% (announces portfolio optimization transactions; not adjusting guidance as a result of these transactions)
- RDN +1% (completes a series of capital actions to enhance financial flexibility and approves new $300 mln share repurchase authorization)
Analyst comments:
- NTRA +3.3% (upgraded to Outperform from Mkt Perform at Raymond James)
- MYGN +3.1% (upgraded to Outperform from Mkt Perform at Raymond James)
- GDDY +2.9% (upgraded to Outperform from In-line at Evercore ISI)
- MQ +1.7% (upgraded to Neutral from Underperform at SMBC Nikko)